Impairments in endocannabinoid signaling and depressive illness.
Hill
Matthew N
MN
Laboratory of Neuroendocrinology, The Rockefeller University, 1230 York Ave, New York, NY 10021, USA. mhill@rockefeller.edu
Gorzalka
Boris B
BB
D000339:Affect / Q000187:drug effects*; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology*; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D003863:Depression / Q000139:chemically induced* / Q000378:metabolism*; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D063388:Endocannabinoids; D006801:Humans; D008024:Ligands; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects* / Q000494:pharmacology; D011720:Pyrazoles / Q000009:adverse effects* / Q000494:pharmacology; D012106:Research; D000077285:Rimonabant; D015398:Signal Transduction; D014029:Tobacco Use Disorder / Q000188:drug therapy
D019440:Anti-Obesity Agents; D000928:Antidepressive Agents; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D008024:Ligands; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant